Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation

Autor: Birgit I. Witte, Gerard Dijkstra, L. van de Langerijt, R. A. van Hogezand, Jan C. Roos, Bas Oldenburg, Nathalie Bravenboer, Marieke Pierik, Paul Lips, A.A. van Bodegraven, J. C. Netelenbos, Maurice G. Russel, A.E. Oostlander, P.C.M. Stokkers, Daan W. Hommes, Vincent K. Dik, C.J. van der Woude

Publikováno v: Gut, 63(9), 1424-1430. BMJ Publishing Group
Gut, 63(9), 1424-1430
van Bodegraven, A A, Bravenboer, N, Witte, B I, Dijkstra, G, van der Woude, C J, Stokkers, P C M, Russel, M G, Oldenburg, B, Pierik, M, Roos, J C, van Hogezand, R A, Dik, V K, Oostlander, A E, Netelenbos, J C, van de Langerijt, L, Hommes, D W & Lips, P T A M 2014, ' Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation ', Gut, vol. 63, no. 9, pp. 1424-1430 . https://doi.org/10.1136/gutjnl-2013-305523
Gut, 63(9), 1424-1430. BMJ PUBLISHING GROUP

Objective Osteoporosis and fractures are frequently encountered in patients with Crohn's disease. In order to prevent fractures, treatment with bone protecting drugs appears warranted early in the course of bone disease when bone loss is not yet prom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::972ee1ff4fc547c64ffd38a370eea495
https://research.vu.nl/en/publications/3e5eb9d2-39ae-44da-9431-28c535509bc1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.